Clinical trial

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT06973161

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2025-06-10

PhaseN/A

Study timeline

Study start (actual)2025-06-10Date precision: day

Registry last updated2026-04-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Bladder Cancerunresolved

Biliary Tract Cancerunresolved

Cervical Cancerunresolved

Endometrial Cancerunresolved

Ovarian Cancerunresolved

Pancreatic Cancerunresolved

Colorectal Cancerunresolved

Lung Cancerunresolved

Other Tumorsunresolved

Interventions

Sponsors & collaborators

AstraZenecalead sponsor

Daiichi Sankyocollaborator

IQVIA Pty Ltdcollaborator

Mapped research locations

HoustonTexas, United States1 MadridSpain1 BarcelonaSpain1 LondonUnited Kingdom1 ParisFrance1 BerlinGermany1 ValenciaSpain1 MarseilleFrance1 ViennaAustria1 LilleFrance1 LondonOntario, Canada1 NiceFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06973161 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.